Have a feature idea you'd love to see implemented? Let us know!

BLUE bluebird bio Inc

Price (delayed)

$0.466

Market cap

$90.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.22

Enterprise value

$336.72M

bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union - ...

Highlights
The revenue is up by 20% since the previous quarter
The EPS has increased by 7% since the previous quarter
bluebird bio's debt has increased by 27% YoY but it has decreased by 6% from the previous quarter
The gross profit has plunged by 175% from the previous quarter
The gross margin has plunged by 129% from the previous quarter and by 24% YoY

Key stats

What are the main financial stats of BLUE
Market
Shares outstanding
193.91M
Market cap
$90.36M
Enterprise value
$336.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.96
Price to sales (P/S)
1.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.13
Earnings
Revenue
$54.9M
EBIT
-$279.3M
EBITDA
-$179.15M
Free cash flow
-$221.7M
Per share
EPS
-$2.22
Free cash flow per share
-$1.14
Book value per share
$0.48
Revenue per share
$0.28
TBVPS
$2.73
Balance sheet
Total assets
$545.19M
Total liabilities
$492.21M
Debt
$390.42M
Equity
$52.98M
Working capital
-$94.41M
Liquidity
Debt to equity
7.37
Current ratio
0.68
Quick ratio
0.54
Net debt/EBITDA
-1.38
Margins
EBITDA margin
-326.3%
Gross margin
-37.3%
Net margin
-567.3%
Operating margin
-609.3%
Efficiency
Return on assets
-51.7%
Return on equity
-207.2%
Return on invested capital
-53.3%
Return on capital employed
-113%
Return on sales
-508.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLUE stock price

How has the bluebird bio stock price performed over time
Intraday
0.43%
1 week
-2.96%
1 month
-1%
1 year
-84.15%
YTD
-66.23%
QTD
-10.3%

Financial performance

How have bluebird bio's revenue and profit performed over time
Revenue
$54.9M
Gross profit
-$20.5M
Operating income
-$334.49M
Net income
-$311.44M
Gross margin
-37.3%
Net margin
-567.3%
The gross profit has plunged by 175% from the previous quarter
The gross margin has plunged by 129% from the previous quarter and by 24% YoY
BLUE's operating margin is up by 31% year-on-year and by 12% since the previous quarter
The revenue is up by 20% since the previous quarter

Growth

What is bluebird bio's growth rate over time

Valuation

What is bluebird bio stock price valuation
P/E
N/A
P/B
0.96
P/S
1.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.13
The EPS has increased by 7% since the previous quarter
bluebird bio's equity has plunged by 82% YoY and by 60% from the previous quarter
BLUE's P/B is 52% below its 5-year quarterly average of 2.0 and 26% below its last 4 quarters average of 1.3
BLUE's P/S is 78% below its last 4 quarters average of 7.3
The revenue is up by 20% since the previous quarter

Efficiency

How efficient is bluebird bio business performance
bluebird bio's ROE has decreased by 48% from the previous quarter
The return on sales has declined by 28% year-on-year but it has increased by 11% since the previous quarter
bluebird bio's return on invested capital has decreased by 15% QoQ
bluebird bio's ROA has decreased by 12% from the previous quarter

Dividends

What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLUE.

Financial health

How did bluebird bio financials performed over time
The total assets is 11% greater than the total liabilities
The quick ratio has plunged by 72% YoY and by 31% from the previous quarter
The current ratio has plunged by 68% YoY and by 27% from the previous quarter
BLUE's debt to equity has surged by 133% since the previous quarter
bluebird bio's equity has plunged by 82% YoY and by 60% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.